Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Promius Pharma Launches New Corporate Brand Identity

Promius Pharma LLC, a subsidiary of Dr. Reddy’s Laboratories, unveiled its new visual identity and corporate brand: The Power of Humans Being.

Read More »

Omnicom Health Group launches DDB Health

Omnicom Health Group announced that it is creating DDB Health, a dedicated, integrated healthcare network combining several U.S. and European professional healthcare agencies.

Read More »

Tesaro’s ovarian cancer drug study succeeds

Tesaro Inc.’s experimental ovarian cancer drug niraparib met the main goal of prolonging survival in patients – without the disease worsening – in a late-stage trial.

Read More »

FDA asks for more data on over-the-counter hand sanitizers

The U.S. FDA is requesting additional data to support the safety and effectiveness of certain active ingredients used in topical consumer antiseptic rubs, including hand sanitizers, that are sold over-the-counter.

Read More »

Shire says ADHD drug meets main goal of study

Irish drugmaker Shire Plc said a study testing an experimental drug to treat attention-deficit disorder met the main goal, bringing the drug one step closer to approval in the United States.

Read More »

FDA does not approve Lipocine’s testosterone drug

Lipocine Inc. said its oral testosterone replacement product did not get the approval in the United States, sending the drugmaker’s shares down 52 percent in premarket trading.

Read More »

Esperion Falls on Lack of FDA Clarity for Cholesterol Drug

Esperion Therapeutics is on track to initiate global pivotal Phase 3 studies and global cardiovascular outcomes trial in fourth-quarter 2016 for Bempedoic Acid.

Aligned with global regulatory authorities on a consistent definition of statin intolerance

Read More »

FDA names Pazdur head of new Oncology Center of Excellence

The U.S. Food and Drug Administration’s high-profile cancer drug director, Dr. Richard Pazdur, has been named head of a newly created Oncology Center of Excellence that will coordinate the review of all the agency’s cancer therapeutics.

Read More »

FDA Advisory Committee recommends approval of Jardiance for cardiovascular indication in 12-11 vote

A U.S. Food and Drug Administration Advisory Committee voted 12-11 that substantial evidence exists to establish that Jardiance (empagliflozin) reduces cardiovascular (CV) death in adults with type 2 diabetes and established CV disease. Jardiance, which is marketed by Boehringer Ingelheim and Eli Lilly, is the only oral T2D medicine shown in a clinical trial to reduce the risk of CV death.

Read More »

White House chides Congress for failing to fund Zika

White House spokesman Josh Earnest chided Republicans for failing to push forward with the president’s request for funding to combat the Zika virus and address an urgent public health crisis.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom